Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hut 8 Corp (HUT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

HUT trades at $102.22, down 3.77% over 24 hours, with a bearish technical signal and key support at $98. The company reported a net loss of $226.15 million in 2025 despite revenue growth, but recent earnings beats and a strategic pivot to AI infrastructure have driven positive analyst sentiment. Strong institutional backing is evident with $4.25 billion in project financing secured in June 2026.

Outlook remains speculative with high execution risk amid the business transition, though Wall Street consensus is bullish with a $135.63 price target. Key risks include sustained negative cash flow, competitive pressures in data centers, and reliance on successful AI project deployment to achieve profitability.